# Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

> **NCT06981637** · PHASE2 · RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 81 (estimated)

## Conditions studied

- Advanced Soft Tissue Sarcoma

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT06981637
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981637, "Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06981637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*